Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Neuroscience

      Neuroscience

      Despite advancements in neuroscience over the past 60 years, unmet need persists for people living with disorders of the nervous system with neurological conditions being the third most common cause of disability and premature death in Europe.[1] However, there has been significant progress in understanding and treating these diseases. We never stop pushing the boundaries of what is possible to the benefit of the patients.

      We are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological autoantibody diseases. Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
      JNJ_BodyIllustration_Interior_Organ_BrainProfile_Colorway02
      Nervous system disorders are more common than you think
      Central nervous system disorders are the second leading cause of death worldwide, and it is estimated that one third of people living in Europe will be affected by a neurological disorder in their lifetime.[2][3]

      We are determined to continue to increase our understanding of nervous system disorders by supporting and engaging with patients, through open dialogue and innovative treatments.
      Female doctor discussing with patient in medical room at hospital
      Holding patients and caregivers at our core
      Our ultimate responsibility remains to our patients who, alongside caregivers, are at the heart of everything we do.

      We cannot look at neuroscience through the lens of science alone. Each person’s experience of a nervous system disease is uniquely influenced by personal, medical, environmental and social factors.[4] It is essential to work in partnership with the patient community to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.

      This is why we work with around 30 patient and carer organisations across Europe to enhance our understanding of living with nervous system diseases. We are part of a broadly-based healthcare company, with a decentralised structure which assures that we remain focused on the markets in every therapeutic and geographical area that we serve.
      JJIM_Photo_ProteinMaker_09_4406 10.17.05 AM.jpg
      Leading the way through innovation
      Our medications and innovations have helped improve the quality of care for millions of people living with neuropsychiatric conditions.

      Today, we are committed to maintaining innovative Research and Development (R&D) that solves for unmet needs across nervous system disorders.
      We are immensely proud of the many ground-breaking therapies J&J has pioneered over the course of our 60+ year legacy in Neuroscience. The focus is on pushing the boundaries of what’s possible, evolving our work and knowledge to include neurological and autoantibody diseases.

      Johnson & Johnson's regional innovation teams operate out of four Innovation Centers in life science hubs, and incubation and acceleration with JLABS is available through 13 locations across the globe and virtually. Our Neuroscience team is also pioneering holistic “predict and pre-empt” paradigms that involve early diagnostics and patient management programmes.
      Leveraging shared pathology across diseases to broaden therapeutic opportunities

      Significant unmet treatment need exists for a range of serious autoantibody mediated autoimmune diseases, including certain neurologic and neuromuscular disorders.[5] Autoantibody diseases are caused by pathogenic antibodies made by one’s own body that attack organs and/or tissues. [6][7][8][9][10][11][12][13][14]

      Autoantibody diseases are associated with significant morbidity and mortality worldwide. [15] They include a large and varied group of more than 80 chronic autoimmune and acute alloimmune conditions, that span rare and prevalent diseases. [5][15][16][17][18] European studies indicate that between 7.6 and 10.2% of the continental population are affected by severe autoantibody diseases, with many patients without safe, effective treatments for their conditions.[19][20][21]

      Johnson & Johnson is committed to deepening our research in neurologic and neuromuscular conditions such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, to help address the significant unmet need for therapies and treatments for patients.

      Our collaborations
      Our global presence and cross-business portfolio provide us with the flexibility to build strong relationships and become the partner of choice for many collaborative opportunities in both established and emerging markets. In emerging markets, our vision is to enable the delivery of quality medicines, harness growth and expand businesses.

      Our alliances take many forms, but our goal is always the same: to advance scientific research and deliver solutions that provide value to patients, physicians and society. We actively pursue new ways of collaborating in our core areas of interest and seek out like-minded health and technology companies to partner with.
      JJ_Photo_Portrait of woman on beach_STOCK_WST1048338w5024h3350_4Star.jpg
      Neuropsychiatric disorders
      neuroscience_goal.jpg
      Neurodegenerative disorders
      neuro_banner.jpg
      Neurological & neuromuscular disorders
      Alzheimer’s disease support
      Additional support for Alzheimer’s disease, major depressive disorder and schizophrenia can be accessed via the JanssenWithMe Mental Health support webpages.
      Learn more
      Our extensive research and innovations aim to improve the quality of care for millions of people with neurological conditions. We’ve equipped ourselves with the knowledge, tools and technology to expand our focus into the full range of psychosis spectrum disorders and mood dysregulation, and by leveraging shared pathology across disease areas to broaden therapeutic opportunities and develop innovations for populations with high unmet needs - such as, for instance in neurodegenerative and neurological disorders. We’re motivated by making a real difference for not just patients, but for society as a whole.”
      Dr. Tamara Werner-Kiechle
      EMEA THERAPEUTIC AREA LEAD, CENTRAL NERVOUS SYSTEM & PULMONARY HYPERTENSION

      References

      [1] Deuschl G, et al. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):E551-E567.

      [2] Open Access Government 2019. Tackling the growing burden of brain disorders in Europe. Available at: https://www.openaccessgovernment.org/brain-disorders-in-europe/72909/. Last accessed July 2023

      [3] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392:1789-1858.

      [4] PsychGuides.com. Neurological Problem Symptoms, Causes and Effects. Available at: https://www.psychguides.com/neurological-disorders/. Accessed July 2023.

      [5] Ludwig RJ, et al. Mechanisms of Autoantibody-Induced Pathology. Front Immunol. 2017;8:603. Doi:10.3389/fimmu.2017.00603.

      [6] Momenta Pharmaceuticals. Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN. GlobeNewswire News Room. Published July 28, 2020. Accessed June 2024. https://www.globenewswire.com/news-release/2020/07/28/2068533/0/en/Momenta-Pharmaceuticals-Announces-FDA-Rare-Pediatric-Disease-Designation-for-Nipocalimab-in-HDFN.html.

      [7] Osanan GC, Silveira Reis ZN, Apocalypse IG, et al. Predictive factors of perinatal mortality in transfused fetuses due to maternal alloimmunization: what really matters? J Matern Fetal Neonatal Med. 2012;25(8):1333-1337. Doi:10.3109/14767058.2011.633668 https://pubmed.ncbi.nlm.nih.gov/22046976/.

      [8] Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30. doi:10.1038/s41572-019-0079-y https://pubmed.ncbi.nlm.nih.gov/31048702/.

      [9] Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335. Doi:10.1186/s12883-019-1573-2 https://pubmed.ncbi.nlm.nih.gov/31864345/.

      [10] Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11:538. doi:10.3389/fneur.2020.00538 https://pubmed.ncbi.nlm.nih.gov/32714266.

      [11] Schett G, Teitelbaum SL. Osteoclasts and Arthritis. J Bone Miner Res. 2009;24(7):1142-1146. doi:10.1359/jbmr.090533 https://pubmed.ncbi.nlm.nih.gov/19557892/.

      [12] Kocijan R, Harre U, Schett G. ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep. 2013;15(10):366. doi:10.1007/s11926-013-0366-7 https://pubmed.ncbi.nlm.nih.gov/23955066/.

      [13] Sieghart D, Platzer A, Studenic P, et al. Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. Front Immunol. 2018;9:876. doi:10.3389/fimmu.2018.00876 https://pubmed.ncbi.nlm.nih.gov/29740454/.

      [14] Taylor PC, Schett G, Fowzia I, et al. Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study. Data presentation at American College of Rheumatology Convergence 2023, November 10-15.

      [15] Eggert M, Zettl UK, Neeck G. Autoantibodies in autoimmune diseases. Curr Pharm Des. 2010;16(14):1634-1643. doi:10.2174/138161210791164144 https://pubmed.ncbi.nlm.nih.gov/20196735.

      [16] Quick MB Jen Christiansen,Miriam. The Terrible Toll of 76 Autoimmune Diseases. Scientific American. doi:10.1038/scientificamerican0921-31 https://www.scientificamerican.com/article/the-terrible-toll-of-76-autoimmune-diseases.

      [17] Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754-765. doi:10.1016/j.autrev.2012.02.001.

      [18] Autoimmune Registry, Inc, 2016-2020 https://www.autoimmuneregistry.org/autoimmune-diseases

      [19] Conrad N, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023 Jun 3;401(10391):1878-1890. doi: 10.1016/S0140-6736(23)00457-9

      [20] Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009 Nov-Dec;33(3-4):197-207. doi: 10.1016/j.jaut.2009.09.008. Epub 2009 Oct 9. PMID: 19819109; PMCID: PMC2783422.

      [21] Wofsy D. Strategies for treating autoimmune disease with monoclonal antibodies. West J Med. 1985 Dec;143(6):804-9. PMID: 3911593; PMCID: PMC1306490.

      CP-507437
      June 2025